Literature DB >> 11159568

Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.

R Schellenberg1.   

Abstract

OBJECTIVES: To compare the efficacy and tolerability of agnus castus fruit (Vitex agnus castus L extract Ze 440) with placebo for women with the premenstrual syndrome.
DESIGN: Randomised, double blind, placebo controlled, parallel group comparison over three menstrual cycles.
SETTING: General medicine community clinics. PARTICIPANTS: 178 women were screened and 170 were evaluated (active 86; placebo 84). Mean age was 36 years, mean cycle length was 28 days, mean duration of menses was 4.5 days.
INTERVENTIONS: Agnus castus (dry extract tablets) one tablet daily or matching placebo, given for three consecutive cycles. MAIN OUTCOME MEASURES: Main efficacy variable: change from baseline to end point (end of third cycle) in women's self assessment of irritability, mood alteration, anger, headache, breast fullness, and other menstrual symptoms including bloating. Secondary efficacy variables: changes in clinical global impression (severity of condition, global improvement, and risk or benefit) and responder rate (50% reduction in symptoms).
RESULTS: Improvement in the main variable was greater in the active group compared with placebo group (P<0.001). Analysis of the secondary variables showed significant (P<0.001) superiority of active treatment in each of the three global impression items. Responder rates were 52% and 24% for active and placebo, respectively. Seven women reported mild adverse events (four active; three placebo), none of which caused discontinuation of treatment.
CONCLUSIONS: Dry extract of agnus castus fruit is an effective and well tolerated treatment for the relief of symptoms of the premenstrual syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159568      PMCID: PMC26589          DOI: 10.1136/bmj.322.7279.134

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  12 in total

Review 1.  GABA function in mood disorders: an update and critical review.

Authors:  I S Shiah; L N Yatham
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

2.  The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects.

Authors:  P G Merz; C Gorkow; A Schrödter; S Rietbrock; C Sieder; D Loew; J S Dericks-Tan; H D Taubert
Journal:  Exp Clin Endocrinol Diabetes       Date:  1996       Impact factor: 2.949

3.  Descriptive data analysis: a concept between confirmatory and exploratory data analysis.

Authors:  K Abt
Journal:  Methods Inf Med       Date:  1987-04       Impact factor: 2.176

4.  Agnus castus extracts inhibit prolactin secretion of rat pituitary cells.

Authors:  G Sliutz; P Speiser; A M Schultz; J Spona; R Zeillinger
Journal:  Horm Metab Res       Date:  1993-05       Impact factor: 2.936

5.  Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales.

Authors:  R F Casper; A M Powell
Journal:  Am J Obstet Gynecol       Date:  1986-10       Impact factor: 8.661

6.  Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales.

Authors:  M Steiner; R F Haskett; B J Carroll
Journal:  Acta Psychiatr Scand       Date:  1980-08       Impact factor: 6.392

7.  [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study].

Authors:  A Milewicz; E Gejdel; H Sworen; K Sienkiewicz; J Jedrzejak; T Teucher; H Schmitz
Journal:  Arzneimittelforschung       Date:  1993-07

8.  In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay.

Authors:  H Jarry; S Leonhardt; C Gorkow; W Wuttke
Journal:  Exp Clin Endocrinol       Date:  1994

9.  Treatment of premenstrual tension syndrome with Vitex agnus castus controlled, double-blind study versus pyridoxine.

Authors:  C Lauritzen; H D Reuter; R Repges; K J Böhnert; U Schmidt
Journal:  Phytomedicine       Date:  1997-09       Impact factor: 5.340

10.  Neuroactive flavonoids: new ligands for the Benzodiazepine receptors.

Authors:  J H Medina; H Viola; C Wolfman; M Marder; C Wasowski; D Calvo; A C Paladini
Journal:  Phytomedicine       Date:  1998-05       Impact factor: 5.340

View more
  28 in total

Review 1.  Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety.

Authors:  Joanne Barnes
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

Review 2.  Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 3.  Gynecological management of premenstrual symptoms.

Authors:  Lee P Shulman
Journal:  Curr Pain Headache Rep       Date:  2010-10

4.  The use of herbal and other non-vitamin, non-mineral supplements among pre- and post-menopausal women in Ontario.

Authors:  Katayoon Pakzad; Beatrice A Boucher; Nancy Kreiger; Michelle Cotterchio
Journal:  Can J Public Health       Date:  2007 Sep-Oct

Review 5.  Benign Breast Disease in Women.

Authors:  Angrit Stachs; Johannes Stubert; Toralf Reimer; Steffi Hartmann
Journal:  Dtsch Arztebl Int       Date:  2019-08-09       Impact factor: 5.594

6.  Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis.

Authors:  Andreas Schapowal
Journal:  BMJ       Date:  2002-01-19

Review 7.  Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents.

Authors:  Andrea J Rapkin; Judith A Mikacich
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

Review 8.  Botanicals and Their Bioactive Phytochemicals for Women's Health.

Authors:  Birgit M Dietz; Atieh Hajirahimkhan; Tareisha L Dunlap; Judy L Bolton
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

9.  High-content screening and mechanism-based evaluation of estrogenic botanical extracts.

Authors:  Cassia R Overk; Ping Yao; Shaonong Chen; Shixing Deng; Ayano Imai; Matthew Main; Andreas Schinkovitz; Norman R Farnsworth; Guido F Pauli; Judy L Bolton
Journal:  Comb Chem High Throughput Screen       Date:  2008-05       Impact factor: 1.339

Review 10.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.